Advertisement
Canada markets open in 17 minutes

  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CAD/USD

    0.7301
    -0.0000 (-0.00%)
     

  • CRUDE OIL

    81.24
    -0.66 (-0.81%)
     

  • Bitcoin CAD

    90,584.80
    -66.33 (-0.07%)
     

  • CMC Crypto 200

    1,421.83
    +7.07 (+0.50%)
     

  • GOLD FUTURES

    2,323.40
    -23.00 (-0.98%)
     

  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     

  • 10-Yr Bond

    4.6460
    +0.0230 (+0.50%)
     

  • NASDAQ futures

    17,418.50
    +68.50 (+0.39%)
     

  • VOLATILITY

    16.51
    -0.43 (-2.54%)
     

  • FTSE

    8,036.34
    +12.47 (+0.16%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6841
    -0.0009 (-0.13%)
     
MARKETS LIVE BLOG:

STOCK FUTURES CLIMB AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

5 Reasons Why You Should Bet on CoreLogic (CLGX) Stock

Zacks Equity Research
·3 min read

CoreLogic, Inc. CLGX is a consulting services provider that has performed extremely well lately and has the potential to sustain the momentum in the near term. Consequently, if you haven’t taken advantage of the share price appreciation yet, it’s time you add the stock to your portfolio.

What Makes CoreLogic an Attractive Pick?

An Outperformer: A glimpse of the company’s price trend reveals that the stock has had an impressive run on the bourses in the past year. Shares of CoreLogic have returned a whopping 128%, significantly outperforming the 67.6% rally of the industry it belongs to in the said time frame.

Solid Rank: CoreLogic has a Zacks Rank #1 (Strong Buy). Our research shows that stocks with a Zacks Rank #1 or #2 (Buy) offer attractive investment opportunities. You can see the complete list of today’s Zacks #1 Rank stocks here.

Northward Estimate Revisions: The direction of estimate revisions serves as an important pointer when it comes to the price of a stock. One estimate for 2021 moved north over the past 60 days versus no southward revision, reflecting analysts’ confidence in the company. Over the same period, the Zacks Consensus Estimate for 2021 has climbed 4.2%.

ADVERTISEMENT

Positive Earnings Surprise History: CoreLogic has an impressive earnings surprise history. The company outpaced the consensus mark in all the trailing four quarters, delivering an average beat of 5.3%.

Growth Factors: CoreLogic is working on strategic initiatives aimed at long-term growth. It is investing in products and solutions, operational capabilities, technology platforms and infrastructure to build strong strategic client partnerships. It is building capabilities focused on data quality, structures and visualization, technology platforms, and automation techniques to strengthen its position across multiple verticals and geographies and increase margin expansion capabilities.

Acquisitions, over time, have helped CoreLogic increase its share in mortgage, real estate, insurance, capital markets, public sector and rental property markets. The 2020 acquisition of Location, Inc. has enhanced the company’s offering for property and casualty insurance by expanding capabilities in predictive, location-based analytics. The 2019 acquisition of National Tax Search has expanded commercial tax capabilities for its customers.

Other Stocks to Consider

Some other stocks worth considering in the broader Zacks Business Services sector are Accenture ACN, Charles River Associates CRAI and TeleTech Holdings TTEC. While TeleTech sports a Zacks Rank #1, Accenture and Charles River carry a Zacks Rank #2.

The long-term expected earnings per share (three to five years) growth rate for Accenture, Charles River and TeleTech is pegged at 10%, 13% and 14.7%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Charles River Associates (CRAI) : Free Stock Analysis Report

TeleTech Holdings, Inc. (TTEC) : Free Stock Analysis Report

Accenture PLC (ACN) : Free Stock Analysis Report

CoreLogic, Inc. (CLGX) : Free Stock Analysis Report

To read this article on Zacks.com click here.